Recent Updates
Recently added Catalysts
KYTX Positive Sentiment

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Monday, March 3, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Kyverna Therapeutics will present at the Leerink Partners Global Biopharma Conference on March 10, 2025. CEO Warner Biddle will discuss the company's progress in developing cell therapies for autoimmune diseases. Kyverna's lead candidate, KYV-101, is undergoing Phase 2 trials for stiff person syndrome and myasthenia gravis, among other indications.
Price reaction · baseline $2.59 (2025-03-03 close) · hit after-hours · clean, no other KYTX news in the window
day 0 close
+1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Kyverna Therapeutics is actively developing innovative cell therapies.
  • The company is presenting at a significant biopharma conference.
  • Kyverna's lead therapy candidate is advancing through clinical trials.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+37%
120-day peak, hindsight
Typical move
5%
average across 6 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
KYV-101 anti-CD19 CAR-T cell therapy
Phase 1 · Multiple Sclerosis

Full Press Release Details

EMERYVILLE, Calif.,March 3, 2025/PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced thatWarner Biddle, Chief Executive Officer of Kyverna, will present at the Leerink Partners Global Biopharma Conference inMiami, FLonMonday, March 10, 2025, at3:00 p.m. ET.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website atir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference.

About Kyverna TherapeuticsKyverna Therapeutics, Inc. (Nasdaq:KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase 2 trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. Kyverna is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for it to advance into late-stage development. Its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. For more information, please visithttps://kyvernatx.com.

Contact:Investors:[email protected]Media:[email protected]

Frequently Asked Questions

When will Kyverna present at the conference?

Kyverna will present at the Leerink Partners Global Biopharma Conference on March 10, 2025.

Who is presenting for Kyverna Therapeutics?

Warner Biddle, the CEO of Kyverna, will be the presenter.

What is Kyverna's lead therapy candidate?

Kyverna's lead candidate is KYV-101, aimed at treating autoimmune diseases.

Where can I access the presentation webcast?

The live webcast can be accessed via the Investors section of Kyverna's website.

ShareAdd on Google
Tags: KYTX Viatris Investor Conferences Healthcare Kyverna Therapeutics biopharma conference cell therapies autoimmune diseases
Last updated: Mar 3, 2025

Biotech snapshot

Cash runway
$199M liquidity · $13M/mo burn
~15 mo
Low dilution risk
Lead asset
KYV-101 anti-CD19 CAR-T cell therapyPhase 1
Multiple Sclerosis →

Catalyst track record

+37%
best trade around KYTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for KYTX.

See every catalyst's timing & PoA →